Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250155 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Genentech.
- Active
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT04250155: Active Phase 1 study of Solid Tumors, sponsored by Genentech.
NCT04250155 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Genentech. The registered enrollment target is 195 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04250155, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG XmAb24306
Study Locations (20)
Other
- Instituto do Cancer do Estado de Sao Paulo - ICESP - São Paulo
- Universitair Medisch Centrum Groningen - Groningen
- Seoul National University Bundang Hospital - Seongnam-si
- Seoul National University Hospital - Seoul
- Severance Hospital Yonsei University Health System - PPDS - Seoul
- Asan Medical Center - PPDS - Seoul
Lombardy
- Fondazione IRCCS Istituto Nazionale dei Tumori - Milan
- Istituto Europeo Di Oncologia - Milan
- Istituto Clinico Humanitas - Rozzano
California
- Stanford Health Centre - Palo Alto - Palo Alto
- University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center - San Francisco
Arizona
- Honor Health Research Institute - Scottsdale
Connecticut
- Yale University - New Haven
Michigan
- City of Hope Comprehensive Cancer Center - Ann Arbor
Tennessee
- SCRI Oncology Partners - Nashville
Victoria
- Parkville Cancer Clinical Trial Unit (PCCTU) - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 1 |
What the registry record for NCT04250155 still lists
NCT04250155 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04250155 names 20 study sites across 12 states, led by Other, Lombardy, California.
Frequently Asked Questions
What is clinical trial NCT04250155 about?
NCT04250155 is a clinical study titled "An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT04250155?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2020-03-09. Estimated completion is 2026-06-15.
What conditions does trial NCT04250155 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT04250155?
The interventions under investigation include: Atezolizumab (DRUG), XmAb24306 (DRUG).
Who is sponsoring clinical trial NCT04250155?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04250155 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04250155's enrollment target sits among peer trials
195 30th of 125 higher than 96 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI